FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
142 letters match. Newest first.
-
DrugsNanjing Hanxin Pharmaceutical Technology Co. Ltd.
FDA warns Nanjing Hanxin of drug-ingredient quality failures and poor supplier oversight; its drugs face U.S. import detention.
High risk -
DrugsPritam International Private Limited
Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.
High risk -
DrugsZhejiang Gaorong Cosmetic Co., Ltd.
FDA cited Zhejiang Gaorong Cosmetic for OTC drug CGMP violations in component testing and quality unit oversight.
High risk -
DrugsSignature Formulations LLC
FDA warns Signature Formulations about contaminated contract-manufactured drug products and cross-contamination at its Phoenix facility.
High risk -
DrugsSnugZ USA, Inc.
SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.
High risk -
DrugsEurofins SF Analytical Laboratories, Inc.
FDA warned Eurofins SF Analytical Laboratories, a contract drug-testing lab, that it kept incomplete microbial test records and skipped required investigations.
High risk -
DrugsTCI Co., Ltd BioCosme PABP BRANCH
FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.
High risk -
AnimalNeogen Corporation
FDA found Neogen's HYCOAT animal drug contaminated and made under insanitary conditions after horse deaths.
High risk -
DrugsBentley Laboratories LLC
Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.
High risk -
AnimalStokes Healthcare Inc. dba Epicur Pharma
FDA warned Epicur Pharma over website claims for compounded omeprazole and buprenorphine animal drugs that are false or misleading.
High risk -
BiologicsStephen J. Fallon, Ph.D.
FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.
High risk -
DrugsJabil Inc.
FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.
High risk -
DrugsSuretec Innovations, LLC
Suretec Innovations failed manufacturing quality rules for OTC sanitizing wipes and did not list a private-label wipe.
High risk -
DrugsEugia Pharma Specialities Limited
FDA warned Eugia Pharma Specialities that flawed aseptic line design and poor aseptic practices at its Kolthur Village plant risk contaminating sterile injectables.
High risk -
DrugsAuriga Research Pvt. Ltd.
Auriga Research, an Indian contract drug testing lab, failed to keep complete lab records and properly investigate failing test results.
High risk -
DrugsSafrel Pharmaceuticals LLC
FDA warned Safrel Pharmaceuticals, an OTC drug labeler in Dayton, New Jersey, that it lacked quality oversight of its suppliers and shipped adulterated drugs.
High risk -
AnimalDeJong Family Dairy, LLC
FDA warned DeJong Family Dairy that it treated cows with an animal drug in ways the label and a veterinarian did not allow.
Medium -
DrugsLico Industries, LLC., d.b.a. American Towelette Company
FDA warns Lico Industries (American Towelette) that its OTC drug wipes are adulterated due to poor quality oversight, dirty equipment and falsified records.
High risk -
DrugsWoodbine Products Company Inc.
Inspection found Woodbine Products, an Ohio OTC drug maker, failed to test incoming ingredients like glycerin and propylene glycol for identity.
High risk -
DevicesKoven Technologies, Inc.
FDA warns Koven Technologies that its Bidop 3 Doppler was labeled for fetal use without clearance and had quality system violations.
High risk -
BiologicsGenzyme Ireland Limited
Genzyme Ireland's Waterford biologics plant cited for quality unit and data integrity failures across two licensed products.
High risk -
DrugsHuons Co., Ltd.
FDA cites Huons in South Korea for data integrity and sterility failures in drug manufacturing.
High risk -
DrugsSante Manufacturing Inc.
Sante Manufacturing’s OTC drugs have significant CGMP violations, including missing identity testing for a high-risk component and inadequate process validation and quality oversight.
High risk -
DrugsHubei Gedian Humanwell Pharmaceutical Co., Ltd.
FDA: Hubei Gedian Humanwell API plant has scratched, stained equipment and weak quality unit oversight.
High risk -
DrugsGopaldas Visram & Co., Ltd.
FDA warns Indian OTC drug maker Gopaldas Visram over talc asbestos testing and data integrity failures.
High risk -
DrugsLaboratorios Dr. Collado S.A.
FDA warns Laboratorios Dr. Collado over inadequate asbestos testing and quality oversight for talc-containing over-the-counter drugs.
High risk -
DrugsRevlon Group Holdings, LLC
FDA cited Revlon's Oxford, NC over-the-counter drug plant for failing to test talc for asbestos and weak quality oversight.
High risk -
DrugsPLZ Corp
FDA warned PLZ Corp over an OTC talc drug made in Mississauga without asbestos testing and with deficient component controls.
High risk -
DrugsJose M. Carpio, M.D.
FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.
Medium -
DrugsMedline Inc
FDA warned Medline Inc about repeated Bacillus cereus contamination in its drug products and inadequate investigations.
High risk -
DrugsLaboratorios Jaloma S.A. de C.V.
FDA found Laboratorios Jaloma’s OTC drug lab records were inaccurate, microbial tests unvalidated, and electronic data missing or uncontrolled.
High risk -
DrugsGC America, Inc.
FDA warned GC America after an inspection found inadequate component testing, stability data, and quality oversight for its OTC drugs.
High risk -
BiologicsAdnan Dahdul, MD
FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.
High risk -
DrugsNaseem A. Jaffrani, M.D.
FDA says clinical investigator Dr. Naseem Jaffrani failed to report serious adverse events to sponsors within 24 hours in two drug trials.
High risk -
DrugsHarbin Jixianglong Biotech Co., Ltd.
FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.
High risk -
AnimalThe Fish Aid
FDA warned The Fish Aid it sells unapproved, unlisted antibiotics for aquarium fish and birds without veterinary oversight.
High risk -
DrugsAva Inc.
FDA warned Ava Inc. about adulterated drugs after an inspection found data-integrity failures and hidden trial injections in its Willowbrook, Illinois lab.
High risk -
DrugsFoshan Miwei Cosmetics Co., Ltd.
FDA warns Foshan Miwei Cosmetics over manufacturing practice failures and unapproved, misbranded over-the-counter (OTC) sunscreen drugs; drugs on import alert.
High risk -
DrugsChemco Corporation
FDA warns Chemco Corporation about CGMP failures and unapproved, misbranded OTC drug products from its Miami Lakes facility.
High risk -
DrugsEhsan Sadri, M.D.
FDA warns Dr. Ehsan Sadri that two ineligible subjects received an investigational drug in clinical trials.
High risk -
DrugsMicrobiological Testing & Consulting, LLC
FDA warned contract testing lab Microbiological Testing & Consulting over CGMP violations in drug product microbiological testing.
High risk -
DrugsYangzhou H&R Plastic Daily Chemical Co., Ltd.
Yangzhou H&R Plastic Daily Chemical, a Chinese contract manufacturer, lacked release testing and CGMP controls for its OTC drug.
High risk -
DrugsNovo Nordisk Inc.
FDA warns Novo Nordisk over failures to report and investigate serious unexpected adverse drug experiences for drugs including semaglutide.
High risk -
DrugsA. Nelson & Co. Ltd.
London homeopathic drug maker A. Nelson & Co. shipped children's products without microbial testing and discarded quality records.
High risk -
DrugsAQ USA Inc., d.b.a Ross Healthcare Inc.
FDA warns AQ USA/Ross Healthcare over current good manufacturing practice violations in drugs, including missing microbial testing and inadequate component and stability controls.
High risk -
DrugsBertrand P. Cole, D.O.
FDA warns Dr. Bertrand P. Cole that he gave four trial subjects too much drug by not following the study plan.
High risk -
DrugsMark S. Dacey, M.D.
FDA warns Dr. Mark S. Dacey that a trial subject underwent an optional eye-fluid sampling procedure after twice declining consent.
High risk -
DrugsCenter For Immunology Science, LLC
FDA cites Center for Immunology Science for a clinical trial of heat-killed Mycobacterium smegmatis without an Investigational New Drug application.
High risk -
DrugsProdrome Sciences USA, LLC
Prodrome Sciences studied its supplement ProdromeNeuro Oil as a dementia drug in 29 people without first filing an IND, FDA says.
High risk -
DrugsIntegrity Partners Group
FDA warns Integrity Partners Group about manufacturing failures at its Chemisphere drug plant, including inadequate testing, supplier verification, cleaning, and process validation.
High risk